230 related articles for article (PubMed ID: 27448973)
1. PIM kinases as therapeutic targets against advanced melanoma.
Shannan B; Watters A; Chen Q; Mollin S; Dörr M; Meggers E; Xu X; Gimotty PA; Perego M; Li L; Benci J; Krepler C; Brafford P; Zhang J; Wei Z; Zhang G; Liu Q; Yin X; Nathanson KL; Herlyn M; Vultur A
Oncotarget; 2016 Aug; 7(34):54897-54912. PubMed ID: 27448973
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
Chen LS; Redkar S; Taverna P; Cortes JE; Gandhi V
Blood; 2011 Jul; 118(3):693-702. PubMed ID: 21628411
[TBL] [Abstract][Full Text] [Related]
3. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
[TBL] [Abstract][Full Text] [Related]
4. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.
Saurabh K; Scherzer MT; Shah PP; Mims AS; Lockwood WW; Kraft AS; Beverly LJ
Oncotarget; 2014 Sep; 5(18):8503-14. PubMed ID: 25238262
[TBL] [Abstract][Full Text] [Related]
5. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
6. Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition.
Iqbal A; Eckerdt F; Bell J; Nakano I; Giles FJ; Cheng SY; Lulla RR; Goldman S; Platanias LC
Oncotarget; 2016 May; 7(22):33192-201. PubMed ID: 27120806
[TBL] [Abstract][Full Text] [Related]
7. PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells.
Siu A; Virtanen C; Jongstra J
Oncotarget; 2011 Dec; 2(12):1134-44. PubMed ID: 22193779
[TBL] [Abstract][Full Text] [Related]
8. Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors.
Wurz RP; Sastri C; D'Amico DC; Herberich B; Jackson CLM; Pettus LH; Tasker AS; Wu B; Guerrero N; Lipford JR; Winston JT; Yang Y; Wang P; Nguyen Y; Andrews KL; Huang X; Lee MR; Mohr C; Zhang JD; Reid DL; Xu Y; Zhou Y; Wang HL
Bioorg Med Chem Lett; 2016 Nov; 26(22):5580-5590. PubMed ID: 27769621
[TBL] [Abstract][Full Text] [Related]
9. PIM kinases: an overview in tumors and recent advances in pancreatic cancer.
Xu J; Zhang T; Wang T; You L; Zhao Y
Future Oncol; 2014 Apr; 10(5):865-76. PubMed ID: 24799066
[TBL] [Abstract][Full Text] [Related]
10. Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.
Batra V; Maris JM; Kang MH; Reynolds CP; Houghton PJ; Alexander D; Kolb EA; Gorlick R; Keir ST; Carol H; Lock R; Billups CA; Smith MA
Pediatr Blood Cancer; 2012 Oct; 59(4):749-52. PubMed ID: 22052829
[TBL] [Abstract][Full Text] [Related]
11. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
Chatterjee S; Chakraborty P; Daenthanasanmak A; Iamsawat S; Andrejeva G; Luevano LA; Wolf M; Baliga U; Krieg C; Beeson CC; Mehrotra M; Hill EG; Rathmell JC; Yu XZ; Kraft AS; Mehrotra S
Clin Cancer Res; 2019 Feb; 25(3):1036-1049. PubMed ID: 30327305
[TBL] [Abstract][Full Text] [Related]
12. PIM kinases 1, 2 and 3 in intracellular LIF signaling, proliferation and apoptosis in trophoblastic cells.
Mary Photini S; Chaiwangyen W; Weber M; Al-Kawlani B; Favaro RR; Jeschke U; Schleussner E; Morales-Prieto DM; Markert UR
Exp Cell Res; 2017 Oct; 359(1):275-283. PubMed ID: 28729093
[TBL] [Abstract][Full Text] [Related]
13. PIM kinases facilitate lentiviral evasion from SAMHD1 restriction via Vpx phosphorylation.
Miyakawa K; Matsunaga S; Yokoyama M; Nomaguchi M; Kimura Y; Nishi M; Kimura H; Sato H; Hirano H; Tamura T; Akari H; Miura T; Adachi A; Sawasaki T; Yamamoto N; Ryo A
Nat Commun; 2019 Apr; 10(1):1844. PubMed ID: 31015445
[TBL] [Abstract][Full Text] [Related]
14. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
Brault L; Gasser C; Bracher F; Huber K; Knapp S; Schwaller J
Haematologica; 2010 Jun; 95(6):1004-15. PubMed ID: 20145274
[TBL] [Abstract][Full Text] [Related]
15. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
[TBL] [Abstract][Full Text] [Related]
16. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.
Mahalingam D; Espitia CM; Medina EC; Esquivel JA; Kelly KR; Bearss D; Choy G; Taverna P; Carew JS; Giles FJ; Nawrocki ST
Br J Cancer; 2011 Nov; 105(10):1563-73. PubMed ID: 22015557
[TBL] [Abstract][Full Text] [Related]
17. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
18. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
[TBL] [Abstract][Full Text] [Related]
19. Pim Kinases Promote Migration and Metastatic Growth of Prostate Cancer Xenografts.
Santio NM; Eerola SK; Paatero I; Yli-Kauhaluoma J; Anizon F; Moreau P; Tuomela J; Härkönen P; Koskinen PJ
PLoS One; 2015; 10(6):e0130340. PubMed ID: 26075720
[TBL] [Abstract][Full Text] [Related]
20. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.
Foulks JM; Carpenter KJ; Luo B; Xu Y; Senina A; Nix R; Chan A; Clifford A; Wilkes M; Vollmer D; Brenning B; Merx S; Lai S; McCullar MV; Ho KK; Albertson DJ; Call LT; Bearss JJ; Tripp S; Liu T; Stephens BJ; Mollard A; Warner SL; Bearss DJ; Kanner SB
Neoplasia; 2014 May; 16(5):403-12. PubMed ID: 24953177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
